当前位置: X-MOL 学术MRS Bull. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Nucleic acid delivery and nanoparticle design for COVID vaccines.
MRS Bulletin ( IF 5 ) Pub Date : 2021-09-14 , DOI: 10.1557/s43577-021-00169-2
Jason L Andresen 1 , Owen S Fenton 2
Affiliation  

ABSTRACT Nucleic acid therapeutics offer a new paradigm to rapidly respond to global health problems. The versatility of nucleic acids, especially in RNA therapies, provides the ability to tune levels of specific protein expression, achieving downregulation through short interfering RNA (siRNA) or upregulation by messenger RNA (mRNA) administration. Recent advances in the development of delivery vehicles, including nonviral nanoparticles are crucial to overcome the innate barriers to nucleic acid delivery. Toward this end, current clinical approaches have utilized mRNA and lipid nanoparticles (LNPs) to address the COVID-19 pandemic through novel vaccine strategies, producing efficacious vaccines within one year of sequencing the SARS-CoV-2 genome. Here, we review fundamental concepts required to achieve successful nucleic acid delivery, including the design of LNP systems optimized for mRNA vaccine applications. GRAPHIC ABSTRACT

中文翻译:

COVID疫苗的核酸递送和纳米颗粒设计。

摘要 核酸疗法为快速应对全球健康问题提供了一种新范式。核酸的多功能性,特别是在 RNA 疗法中,提供了调节特定蛋白质表达水平的能力,通过短干扰 RNA (siRNA) 实现下调或通过信使 RNA (mRNA) 给药实现上调。包括非病毒纳米颗粒在内的运载工具开发的最新进展对于克服核酸运载的先天障碍至关重要。为此,目前的临床方法已利用 mRNA 和脂质纳米颗粒 (LNP) 通过新的疫苗策略来应对 COVID-19 大流行,在对 SARS-CoV-2 基因组进行测序的一年内生产出有效的疫苗。在这里,我们回顾了实现成功核酸递送所需的基本概念,包括针对 mRNA 疫苗应用优化的 LNP 系统的设计。图形摘要
更新日期:2021-09-14
down
wechat
bug